F1000 highlights
暂无分享,去创建一个
[1] M. Takahama,et al. Operative indications for lung cancer with idiopathic pulmonary fibrosis. , 2007, The Thoracic and cardiovascular surgeon.
[2] S. Katsaragakis,et al. Postresectional pulmonary oxidative stress in lung cancer patients. The role of one-lung ventilation. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[3] I. Mikami,et al. Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. , 2004, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
[4] K. Nakata,et al. [Fatal acute exacerbation of idiopathic pulmonary fibrosis/usual interstitial pneumonia initially in the right lung after surgery lobectomy for left lung cancer]. , 2004, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.
[5] T. Okamoto,et al. Clinical analysis of interstitial pneumonia after surgery for lung cancer. , 2004, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.
[6] Y. Ohtani,et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. , 2003, Internal medicine.
[7] A. Nicholson,et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. , 2003, The Journal of thoracic and cardiovascular surgery.
[8] E. Martinod,et al. Surgical resection of lung cancer in patients with underlying interstitial lung disease. , 2002, The Annals of thoracic surgery.
[9] D. Schroeder,et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. , 2001, The European respiratory journal.
[10] D. Schroeder,et al. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. , 2000, American journal of respiratory and critical care medicine.
[11] J. Fujita,et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. , 1998, The European respiratory journal.
[12] I. D. Johnston,et al. Clinical Investigations: BAC, UIP, SODSurvival in Patients With Cryptogenic Fibrosing Alveolitis: A Population-Based Cohort Study , 1998 .
[13] M. Yoshida,et al. The effect of low-dose inhalation of nitric oxide in patients with pulmonary fibrosis. , 1997, The European respiratory journal.
[14] S. Yokota,et al. [Characteristics and management of patients with lung cancer and idiopathic interstitial pneumonia]. , 1996, Nihon Kyobu Shikkan Gakkai zasshi.
[15] Y. Mizushima,et al. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. , 1995, Chest.
[16] H. Kreisman,et al. Fatal pulmonary toxicity following oral etoposide therapy. , 1995, Lung cancer.
[17] G. Hunninghake,et al. Approaches to the treatment of pulmonary fibrosis. , 1995, American journal of respiratory and critical care medicine.
[18] H. Magnussen,et al. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. , 1994, The European respiratory journal.
[19] M. Lamy,et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.
[20] D. Schwartz,et al. Determinants of survival in idiopathic pulmonary fibrosis. , 1994, American journal of respiratory and critical care medicine.
[21] K. Nakata,et al. [Acute exacerbation in idiopathic interstitial pneumonia]. , 1984, Nihon Kyobu Shikkan Gakkai zasshi.
[22] E. Anderson. Hudson et al. , 1977 .
[23] A. Liebow,et al. Relationship of interstitial pneumonia honeycombing and atypical epithelial proliferation to cancer of the lung , 1965, Cancer.
[24] T. Yano,et al. [Prophylactic administration of steroid for interstitial pneumonia after pulmonary resection for lung cancer]. , 2005, Kyobu geka. The Japanese journal of thoracic surgery.
[25] R. Hubbard,et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. , 2000, American journal of respiratory and critical care medicine.
[26] K P Offord,et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.
[27] E. Borden,et al. Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non‐small cell lung cancer , 1986, Cancer.
[28] D. Mapel,et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts , 2022 .